Management of Direct Oral Anticoagulants in Acute Type A Aortic Dissection
This case series demonstrates that preoperative management of DOACs in patients with ATAAD may employ factor repletion with success. Literature review demonstrated a safety signal for heparin insensitivity or pump thrombosis when andexanet-alfa was administered before or while on cardiopulmonary bypass or extracorporeal membrane oxygenation. Our institutional clinical practice guidelines recommend against administration of andexanet-alfa within 4 to 6 hours before heparinization for surgery in ATAAD but recommend considering andexanet-alfa administration when there is life-threatening bleeding after heparin reversal that is thought to be due to Xa-inhibition with laboratory evidence of elevated anti-Xa activity.
Authors
- Jake Awtry (ORCID: https://orcid.org/0000-0003-1419-6975)
- Ashraf A. Sabe (ORCID: https://orcid.org/0000-0002-0250-9738)
- Robert Semco (ORCID: https://orcid.org/0000-0002-4696-3123)
- Kim De La Cruz
- Thais Faggion Vinholo (ORCID: https://orcid.org/0000-0002-9572-6861)
- Asishana A. Osho (ORCID: https://orcid.org/0000-0002-1140-097X)
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Massachusetts General Hospital (US)
Publication Details
- Journal
- Aorta
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1055/a-2542-4290
- Primary Topic
- Aortic Disease and Treatment Approaches
- Type
- article
- Field-Weighted Citation Impact
- 0.00